The National Institutes of Health (NIH) intends to award a non-competitive contract to Frontage Laboratories, Inc. for the synthesis of cyclopentane monomers and SAMT-247, along with preclinical studies to support potential anti-cancer and anti-HIV treatments. The work will be performed in Exton, Pennsylvania, under a simplified acquisition procedure not exceeding the simplified acquisition threshold of $350,000. This opportunity supports the National Institute of Diabetes and Digestive and Kidney Diseases’ research into molecules with potential as clinical candidates for cancer and HIV prevention. Interested parties must submit a capability statement, technical and cost-price proposals, and other required information by July 13, 2026. All respondents must have an active SAM registration and submit responses electronically to the specified contracting officer.